IBM Stock Keeps Winning in Quantum. The Stock Is Still Stuck Near Its Lows
IBM's stock is near lows despite quantum advancements. Q2 revenue grew 1% to $17.16B, but mainframe revenue fell 42%. CEO Krishna attributes the drop to execution issues, not demand collapse. Analysts see potential 37% total return, with a target price of ~$322. The company's recurring software revenue grew 8%, and it acquired HRL Laboratories for quantum research.
How this was made
The 30-second read
Why it matters
The earnings miss highlights execution risk in IBM’s legacy hardware business, but recurring software growth and quantum investments offer a longer‑term upside narrative.
Market read
IBM’s earnings miss could trigger short‑term price volatility, while its software and quantum strategies may influence sector sentiment.
What to watch
Quantum acquisition and long‑term cash flow generation may provide a valuation floor not reflected in the short‑term price reaction.
Background
IBM’s Q2 2026 earnings showed a modest 1% revenue increase to $17.16 bn, driven by recurring software growth while core mainframe hardware revenue fell sharply.
Ticker impact
IBM reported a 42% drop in mainframe revenue and a 9% decline in transaction processing software in Q2, causing a 25% single‑day stock fall and raising concerns about execution versus demand.
Potential further downside of 5‑10% if deferred deals fail to convert; upside of 8‑12% if software ARR accelerates as projected.
Large‑cap earnings miss with clear revenue shortfall and management commentary provides a concrete catalyst; the magnitude of the miss and guidance give a clear directional bias.
Market effects
Mainframe and enterprise software peers may see pressure as investors reassess execution risk versus demand trends.
U.S. technology sector could face slight pullback amid broader concerns on legacy hardware revenue.
Limited; IBM’s results primarily affect U.S. and global enterprise‑IT investors.
Counterpoint
If deferred mainframe deals convert and software ARR accelerates, IBM could outperform peers despite the earnings miss.
Key entities
- ExecutiveArvind Krishna
IBM CEO who emphasized execution issues and deferred deal conversion.
- AcquisitionHRL Laboratories
Quantum acquisition adding silicon‑spin qubit expertise.
